Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: Enzamet (Anzup 1304)

805TiPRANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN ANDROGEN DEPRIVATION THERAPY WITH RADIATION THERAPY FOR HIGH RISK, CLINICALLY LOCALISED, PROSTATE CANCER: ENZARAD (ANZUP 1303).

S. Williams1, I.D. Davis2, C. Sweeney3, M.R. Stockler4, A. Martin4, A.P. Long4, S. Yip4, X. Coskinas4, P. Nguyen5 Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, AUSTRALIA Eastern Health Clinical School, Monash University, Melbourne, VIC, AUSTRALIA Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA, USA NHMRC Clinical Trials Centre, University of...

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

BACKGROUND Whether the addition of radiation therapy (RT) improves overall survival in men with locally advanced prostate cancer managed with androgen deprivation therapy (ADT) is unclear. Our aim was to compare outcomes in such patients with locally advanced prostate cancer. METHODS Patients with: locally advanced (T3 or T4) prostate cancer (n=1057); or organ-confined disease (T2) with eithe...

Androgen Deprivation Therapy for Prostate Cancer

Androgen Deprivation Therapy for Prostate Cancer

AN D R O G E N D E P R I V A T I O N t h e r a p y ( A D T ; h e r e i n defined as medical or surgical castration) is the cornerstone treatment of advanced prostate cancer. In 1941, Huggins and Hodges first noted the beneficial effects of castration and injection of estrogens in patients with metastatic prostate cancer. The biological basis of the effect of ADT, the almost ubiquitous expressio...

Androgen deprivation therapy for prostate cancer.

CONTEXT Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in US men. Androgen deprivation therapy (ADT), specifically surgical or medical castration, is the first line of treatment against advanced prostate cancer and is also used as an adjuvant to local treatment of high-risk disease. OBJECTIVE To review systematically the evidence on the risk...